This clinical trial is focused on studying the treatment of acute allergic reactions. The treatment being evaluated is a medication called Zeqmelit™ 6 mg, which comes in the form of a mouth-dissolving film. This film contains the active ingredient dexamethasone, a type of medication commonly used to reduce inflammation and suppress the immune system’s response during allergic reactions.

The purpose of the study is to assess how satisfied patients are with using Zeqmelit™ compared to their usual treatment, especially during an acute allergic reaction. Participants in the study will use the mouth-dissolving film and provide feedback on their overall satisfaction, including how safe they feel using it. The study will also gather information on the participants’ experiences with the treatment, such as their choice of treatment and access to it, as well as their perception of its effectiveness.

Throughout the study, participants will be asked to answer questions about their satisfaction and experiences with the treatment. This will help researchers understand how Zeqmelit™ compares to standard treatments for acute allergic reactions. The study is designed to be low-intervention, meaning it aims to minimize any disruption to the participants’ usual treatment routines.